WEST LAFAYETTE, Ind., May 7, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that Scot L. Harper, Ph.D., has been appointed as vice president of clinical operations. Dr. Harper will be responsible for all operational aspects of advancing Endocyte's clinical pipeline, including continued enrollment in the Phase 3 PROCEED and Phase 2b TARGET trials for vintafolide and etarfolatide, and the three new drug candidates scheduled to enter the clinic before the end of 2014.
"Scot has deep expertise in the drug development process and management of all stages of clinical trials, and he will play a key role at Endocyte as we seek to expand and advance our platform," said Ron Ellis, Endocyte's president and chief executive officer. "His experience will help ensure we are able to maximize the value of our unique approach to selecting patients, rapidly bringing meaningful new therapies to these targeted patients."
Dr. Harper brings more than twenty-five years of clinical operations experience to his position at Endocyte. He joins the company from PAREXEL International, where he was the global portfolio director for oncology, overseeing clinical activities for oncology drugs ranging from Phase 1 to Phase 4 of development. Prior to this position, he was the vice president of Novartis' North American clinical operations, where he managed clinical operations of all stages of development, including products such as Gleevec, Tasigna and Diovan. Before this, he was at Eli Lilly and Company, where he held a variety of senior roles, most recently senior director of clinical operations, which included oversight of clinical trials in areas including oncology, neuroscience, diabetes and men's health. Dr. Harper began his career at SmithKline Beecham, where he worked in new product development.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts